Overview
Why was this study done?
The main goal of the study was to find out how effective a vaccine in development for chronic obstructive
pulmonary disease (COPD) is in reducing the number of COPD exacerbations. Exacerbation was defined by the
study doctor. The doctor’s decision was based on symptoms reported by the patient, increased use of COPD
medications or a COPD related hospitalisation.
What was studied? Who was in this study?
• The number of times patients suffered • 606 patients with moderate, severe or very
moderate to severe exacerbation of their severe COPD (245 women and 361 men) from 8
COPD symptoms. countries participated in this study. They were
40 to 80 years old when they got their first study
• Possible vaccine side effects.
injection.
What kind of study was it? Main results
• This was an observer-blind study. Neither • The number of COPD exacerbations was
the study doctor nor the patient knew if a similar in both study groups, even though
vaccine or placebo was given. the vaccine brought about a strong immune
response.
• This was a placebo-controlled study. Half
the patients who participated received • In all, this study revealed no new safety
the study vaccine. The other half received concerns about the study vaccine. There
injections of an inactive placebo. were more serious breathing-related side
effects in patients who received the
inactive placebo injection than the study
vaccine.
NCT number: NCT03281876
EudraCT number: 2017-000880-34